Celgene Co. (NASDAQ:CELG)‘s stock had its “buy” rating reissued by research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Wednesday.

CELG has been the subject of a number of other reports. Cantor Fitzgerald set a $159.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Thursday, April 27th. Leerink Swann reaffirmed a “market perform” rating on shares of Celgene in a research note on Monday, March 20th. Cann reaffirmed a “buy” rating and set a $148.00 price target on shares of Celgene in a research note on Tuesday, April 4th. Robert W. Baird reaffirmed an “outperform” rating and set a $162.00 price target on shares of Celgene in a research note on Wednesday, April 19th. Finally, Canaccord Genuity set a $156.00 price target on shares of Celgene and gave the stock a “buy” rating in a research note on Thursday, January 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $138.89.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Shares of Celgene (NASDAQ:CELG) traded up 0.38% during mid-day trading on Wednesday, hitting $117.75. 2,660,543 shares of the stock traded hands. The firm has a 50 day moving average of $122.17 and a 200 day moving average of $119.79. The stock has a market cap of $91.94 billion, a price-to-earnings ratio of 44.22 and a beta of 1.74. Celgene has a 12 month low of $94.42 and a 12 month high of $127.64.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.21. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The firm had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.04 billion. During the same period in the previous year, the company earned $1.32 EPS. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. On average, equities analysts expect that Celgene will post $7.28 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/05/24/celgenes-celg-buy-rating-reiterated-at-jpmorgan-chase-co.html.

In other news, Director Gilla Kaplan sold 14,033 shares of the company’s stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $123.83, for a total value of $1,737,706.39. Following the sale, the director now directly owns 73,109 shares of the company’s stock, valued at approximately $9,053,087.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rupert Vessey sold 4,000 shares of the business’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $124.42, for a total transaction of $497,680.00. Following the completion of the transaction, the insider now owns 778 shares of the company’s stock, valued at $96,798.76. The disclosure for this sale can be found here. Insiders sold a total of 27,283 shares of company stock worth $3,382,386 over the last ninety days. Insiders own 0.97% of the company’s stock.

Several institutional investors have recently bought and sold shares of CELG. Hellman Jordan Management Co. Inc. MA boosted its position in Celgene by 26.7% in the third quarter. Hellman Jordan Management Co. Inc. MA now owns 14,235 shares of the biopharmaceutical company’s stock worth $1,454,000 after buying an additional 3,000 shares in the last quarter. Rothschild Capital Partners LLC bought a new position in Celgene during the third quarter worth $4,386,000. Stratos Wealth Partners LTD. boosted its position in Celgene by 16.6% in the third quarter. Stratos Wealth Partners LTD. now owns 6,840 shares of the biopharmaceutical company’s stock worth $715,000 after buying an additional 972 shares in the last quarter. NEXT Financial Group Inc boosted its position in Celgene by 30.7% in the third quarter. NEXT Financial Group Inc now owns 5,920 shares of the biopharmaceutical company’s stock worth $619,000 after buying an additional 1,392 shares in the last quarter. Finally, TCI Wealth Advisors Inc. boosted its position in Celgene by 5.2% in the third quarter. TCI Wealth Advisors Inc. now owns 4,033 shares of the biopharmaceutical company’s stock worth $422,000 after buying an additional 198 shares in the last quarter. Hedge funds and other institutional investors own 77.68% of the company’s stock.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

12 Month Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.